SARS-CoV-2 vaccination management in patients with chronic plaque psoriasis DOI Creative Commons

Francesco Bellinato,

Mattia Mazzariol,

Paolo Gisondi

et al.

Published: Aug. 26, 2022

Since December 2020, large vaccination campaigns have been initiated all over the world, changing dramatically course of COVID-19 pandemic.As SARS-CoV-2 vaccines become widely available, dermatologists need to face issues related their safety and efficacy for patients with immune-mediated inflammatory diseases including those psoriasis taking immunomodulatory treatments.According different guideline EuroGuiDerm Guideline, National Psoriasis Foundation International Council recommendations, are candidate whether they on systemic drug treatment or not.Although randomized controlled trials excluded such patients, current real-world data suggest that safe in undergoing treatment.An open issue is treatments will mount a sufficient humoral cellular immune response vaccine.In individuals receiving methotrexate TNF-a inhibitors, impairment waning immunogenicity has reported.Consequently, might require testing assess adequate responses elicited after booster required generate protection against infection.

Language: Английский

SARS-CoV-2 vaccination management in patients with chronic plaque psoriasis DOI Creative Commons

Francesco Bellinato,

Mattia Mazzariol,

Paolo Gisondi

et al.

Published: Aug. 26, 2022

Since December 2020, large vaccination campaigns have been initiated all over the world, changing dramatically course of COVID-19 pandemic.As SARS-CoV-2 vaccines become widely available, dermatologists need to face issues related their safety and efficacy for patients with immune-mediated inflammatory diseases including those psoriasis taking immunomodulatory treatments.According different guideline EuroGuiDerm Guideline, National Psoriasis Foundation International Council recommendations, are candidate whether they on systemic drug treatment or not.Although randomized controlled trials excluded such patients, current real-world data suggest that safe in undergoing treatment.An open issue is treatments will mount a sufficient humoral cellular immune response vaccine.In individuals receiving methotrexate TNF-a inhibitors, impairment waning immunogenicity has reported.Consequently, might require testing assess adequate responses elicited after booster required generate protection against infection.

Language: Английский

Citations

0